Biotechnology

T2 Biosystems

T2 Biosystems released FY2024 Q3 earnings on November 14 After-Market (EST), actual revenue 1.985 MUSD (forecast 2.8 MUSD), actual EPS -0.5654 USD (forecast -0.64 USD)

T2 Biosystems released FY2024 Cumulative 3Q Earnings on November 14 After-Market (EST), Actual Revenue 5.998M USD, Actual EPS -3.8577

T2 Biosystems to Release FY2024 Q3 Earnings on November 14 After-Market EST, Forecast Revenue 2.8 M USD, EPS -0.64 USD

T2 Biosystems Successfully Addresses Patent Opposition in the EU, Focusing on Sepsis Detection Technology

T2 Biosystems' Intention to Participate in H.C. Wainwright 26th Global Investment Conference

T2 Biosystems reports record sepsis detection revenue in Q2 2024

T2 Biosystems expands business through distributors in Malaysia and Indonesia

T2 Biosystems Inc is expected to report quarterly revenue growth and a loss of 97 cents per share

t2 biosystems: sells t2dx instrument, t2bacteria panel, t2candida panel, t2resistance panel through newly appointed designated distributor

T2 Biosystems: Exclusive Distribution Agreement in Hong Kong and Macau

T2 Biosystems Signs Letter of Intent for Strategic Cooperation with ECO LABORATORY

Apellis Pharma

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

U-BX Tech

3 E Network Tech

PMGC

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Bullfrog AI

Jaguar Uranium

Texxon

Classover Holdings - Class B

Kiniksa Pharmaceuticals

MiMedx

Rigel Pharma

CapForce Inc.

OpGen

Vertex Pharma

Argenx

Alnylam Pharma

Beigene

Natera

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

T2 Biosystems(TTOO.US)

T2 Biosystems Stock Performance Chart